Bio-availability and dissolution of three phenytoin preparations for children.
A study of bio-availability of three drug companies' brands of phenytoin preparations (50mg capsule/tablets) was undertaken on 30 children with tonic-clonic or complex partial seizures. Eight children were excluded because of non-compliance and three because of abnormally high serum levels. Phenytoin capsules (Parke Davis) and tablets (Boots) produced significantly higher serum-level profiles than phenytoin tablets (Evans). Seizure frequencies did not differ significantly with the three brands of phenytoin. Dissolution of the three preparations tested in vitro was different. As a result of this study the authors recommend that children remain on the same manufacturer's brand of phenytoin throughout their treatment.
D000293:Adolescent; D001682:Biological Availability; D002214:Capsules; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D010672:Phenytoin / Q000008:administration & dosage* / Q000378:metabolism / Q000627:therapeutic use; D012640:Seizures / Q000188:drug therapy; D012995:Solubility; D013607:Tablets
D002214:Capsules; D013607:Tablets; D010672:Phenytoin